表紙:慢性炎症性脱髄性多発神経炎 (CIDP) (中枢神経系) - 開発中の薬剤:2021年
市場調査レポート
商品コード
1017659

慢性炎症性脱髄性多発神経炎 (CIDP) (中枢神経系) - 開発中の薬剤:2021年

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) - Drugs In Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 96 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
慢性炎症性脱髄性多発神経炎 (CIDP) (中枢神経系) - 開発中の薬剤:2021年
出版日: 2021年06月30日
発行: Global Markets Direct
ページ情報: 英文 96 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

慢性炎症性脱髄性多発神経炎 (CIDP) は、慢性再発性多発神経炎とも呼ばれ、進行性の脚や腕の脱力感や感覚障害を特徴とする神経障害です。末梢神経のミエリン鞘の損傷によって引き起こされます。症状として、初期に近位および遠位の四肢の脱力感、起立性のめまい、手足のしびれなどが挙げられます。

当レポートでは、慢性炎症性脱髄性多発神経炎 (CIDP) (中枢神経系) に対する開発中の薬剤について調査分析し、パイプライン情勢の概要を提供します。

目次

目次

  • イントロダクション
  • レポートの範囲
  • 慢性炎症性脱髄性多発神経炎 (CIDP) - 概要
  • 慢性炎症性脱髄性多発神経炎 (CIDP) - 治療薬の開発
  • パイプラインの概要
  • パイプライン:企業別
  • 開発中の製品:企業別
  • 慢性炎症性脱髄性多発神経炎 (CIDP) - 治療薬の評価
  • 評価:標的別
  • 評価:作用機序別
  • 評価:投与経路別
  • 評価:分子タイプ別
  • 慢性炎症性脱髄性多発神経炎 (CIDP) - 治療薬開発に従事している企業
  • Argenx SE
  • Cellenkos Inc
  • GeNeuro SA
  • Immupharma Plc
  • Johnson & Johnson
  • Octapharma AG
  • Pfizer Inc
  • Sanofi
  • Takeda Pharmaceutical Co Ltd
  • UCB SA
  • 慢性炎症性脱髄性多発神経炎 (CIDP) - 薬剤プロファイル
  • CK-0803 - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • efgartigimod alfa - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • forigerimod acetate - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • hyaluronidase (recombinant, human) + immune globulin (human) - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • immune globulin (human) - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • immune globulin (human) - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • M-254 - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • PF-06755347 - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • rozanolixizumab - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • SAR-445088 - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • temelimab - 薬剤プロファイル
  • 製品の説明
  • 作用機序
  • R&Dの進捗状況
  • 慢性炎症性脱髄性多発神経炎 (CIDP) - 休止中のプロジェクト
  • 慢性炎症性脱髄性多発神経炎 (CIDP) - 開発が中止された製品
  • 慢性炎症性脱髄性多発神経炎 (CIDP) - 製品開発のマイルストーン
  • 注目のニュースとプレスリリース
  • 付録
  • 調査手法
  • カバレッジ
  • 2次調査
  • 1次調査
  • 専門家チームの検証
  • 連絡先
  • 免責事項
図表

List of Tables

List of Tables

  • Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Argenx SE, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Cellenkos Inc, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by GeNeuro SA, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Immupharma Plc, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Johnson & Johnson, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Octapharma AG, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Pfizer Inc, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Sanofi, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline by UCB SA, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects, 2021
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC12861IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy - Drugs In Development, 2021, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline landscape.

Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness of hands and feet.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 2, 3 and 2 respectively.

Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Companies Involved in Therapeutics Development
  • Argenx SE
  • Cellenkos Inc
  • GeNeuro SA
  • Immupharma Plc
  • Johnson & Johnson
  • Octapharma AG
  • Pfizer Inc
  • Sanofi
  • Takeda Pharmaceutical Co Ltd
  • UCB SA
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drug Profiles
  • CK-0803 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • efgartigimod alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • forigerimod acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • M-254 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-06755347 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rozanolixizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAR-445088 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • temelimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Dormant Projects
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Discontinued Products
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Product Development Milestones
  • Featured News & Press Releases
  • Feb 12, 2021: U.S. FDA approves PANZYGA for the treatment of adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Feb 02, 2021: argenx issues statement concerning Efgartigimod
  • Feb 01, 2021: Argenx announces "GO" decision in adhere trial of Efgartigimod in chronic inflammatory demyelinating polyneuropathy following interim analysis
  • May 18, 2020: Final results from the ProCID study of efficacy and safety of 3 different dosages of Panzyga (NewGam) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) presented at AAN 2020
  • Feb 19, 2019: Gliknik to receive $15 million milestone payment from Pfizer following clinical progress with PF-06755347, previously known as GL-2045
  • Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data
  • Feb 22, 2018: GeNeuro receives Orphan Drug Designation from the US FDA for GNbAC1 in chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer